Bitcoin has breached US$100,000 for the first time, propelled by “Trump pump” optimism surrounding the President-elect’s crypto-friendly policies. The cryptocurrency, the largest by market value, climbed to US$102,510 on 5 December, marking a 45% rise since Trump’s election victory in early November. It’s currently trading around US$99,000. Trump’s pro-crypto stance In July 2024, during the […]
Bitcoin at $100K: Making crypto great again Read More »
On Monday, Northern Star Resources (ASX:NST) announced a deal to acquire De Grey Mining (ASX:DEG), including its world-class Hemi Gold Project. The $5bn acquisition, if approved, would see De Grey shareholders receiving 0.119 Northern Star shares for each De Grey share. This represents a 39% premium to De Grey’s closing price last Friday. Over the past
Hot Stocks: Northern Star Resources, Hazer Group, INOVIQ Read More »
The UK Competition and Markets Authority (CMA) has approved the merger of Vodafone (LSE: VOD) and Three UK, ending months of regulatory scrutiny. The new entity will be the country’s largest mobile operator, with over 27 million customers. The £16.5bn deal consolidates two of the UK’s four major mobile network providers and is expected to
Dial “M” for merger: Vodafone and Three’s 16.5bn partnership Read More »
US stocks were lower on Thursday as investors awaited Friday’s big jobs report. The Dow Jones Industrial Average dipped 248.33 points, or 0.55 per cent, to close at 44,765.71. Meanwhile, the Nasdaq Composite slipped 0.18 per cent to end at 19,700.26. The S&P 500 dropped 0.19 per cent, settling at 6,075.11. Traders on Thursday focused
US stocks slide: ASX to open lower Read More »
Shell (LSE: SHEL) and Equinor (OSE: EQNR) have announced plans to combine their North Sea oil and gas assets into a new company, set to become one of the largest producers in the region. The joint venture will be based in Aberdeen. The 50-50 partnership will incorporate Equinor’s holdings in Mariner, Rosebank, and Buzzard fields,
Shell and Equinor to merge North Sea assets Read More »
Mesoblast (ASX:MSB) has announced that the US Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy designation to its Revascor (rexlemestrocel-L) drug for children with hypoplastic left heart syndrome (HLHS). This builds on earlier FDA designations of Rare Pediatric Disease (RPD) and Orphan-Drug (OD) status for the therapy. Mesoblast develops allogeneic (off-the-shelf) cellular medicines
Mesoblast’s Revascor gets FDA nod, but shares dip Read More »
Larvotto Resources (ASX:LRV) has announced a successful $30m equity raising through the placement of 57.7 million new shares at $0.52 each. This two-tranche placement saw strong support from both existing and new institutional investors. The funds, combined with $6.2m from a recently announced antimony prepayment facility and $8m from options conversion, bolster Larvotto’s ability to
Larvotto Resources secures $30m equity raise Read More »
Spartan Resources (ASX:SPR) has secured $220m in funding through an institutional placement to accelerate the restart of operations at its Dalgaranga Gold Project in Western Australia. The placement, conducted at $1.32 per share, received strong backing from domestic and international resource-focused investors. Notably, Ramelius Resources (ASX:RMS), Spartan’s largest shareholder, increased its stake to 19.9% through
Spartan Resources raises $220m Read More »
HMC Capital has announced the acquisition of Neoen’s Victorian renewable energy portfolio for $950m, marking a step in its move into the energy transition sector. The portfolio includes 652MW of operational capacity across wind, solar, and battery energy storage systems (BESS), along with a 2.8GW development pipeline featuring advanced-stage projects. The purchase will seed HMC’s
HMC Capital (ASX:HMC) acquires Neoen’s Victorian renewable portfolio for $950m Read More »
INOVIQ (ASX:IIQ) has announced progress in breast cancer diagnostics, completing a pivotal study for its “neuCA15-3” blood test. The test is designed to detect breast cancer across all stages and major subtypes. It achieved 81% sensitivity (correctly identifying those with breast cancer) and 93% specificity (accurately excluding those without breast cancer). INOVIQ is a biotech
INOVIQ completes study for breast cancer test Read More »
